August 26, 2024

2 Minutes
Medicine

Adcendo ApS and Multitude Therapeutics Inc Sign Licensing Agreement for an ADC Drug Candidate Targeting Tissue Factor

Adcendo ApS (Adcendo) and Multitude Therapeutics Inc (Multitude) have signed a licensing agreement regarding the development of a highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF), known as ADCE-T02. As part of the...
Read More